The Peptide Formulary

The standing caveat. Regulatory status reviewed: July 2026. Regulatory status changes, and it changed twice between 2023 and 2026. Every tag on this page reflects that review date and must be verified against current FDA action, your state board, and your compounding pharmacy before you prescribe. No compounded peptide is an FDA-approved drug, and an FDA approval that attaches to a branded product does not transfer to a compounded preparation of the same molecule. Teaching clinicians to make that distinction — and to keep making it as the rules move — is a graded competency in Module 2 of the curriculum.

• Footnote A. BPC-157, KPV, TB-500 / thymosin beta-4 and MOTS-c appear with the PCAC tag; all four were also among the twelve removed from Category 2 in April 2026. Neither event is an approval.
• Footnote B. Topical cosmetic peptides are regulated as cosmetic ingredients rather than as drugs; they carry the verify-before-prescribing default because status turns on the claim made and the formulation supplied. The same split applies to GHK-Cu: the 2026 Category 2 removal covers the injectable form only.
• Footnote D. Exosome, PRP and PDRN preparations are biologic products, not peptides. No exosome product is FDA-approved for any indication, and FDA has issued public safety notifications about unapproved exosome products; they appear here because the curriculum appraises how they are combined with peptide protocols and what their regulatory posture actually is.
• Footnote C. Glutathione and L-carnosine are, biochemically, peptides. Glutathione is tagged as an adjunctive compound per Empire’s formulary convention, which classifies supplement-channel redox agents alongside the other non-peptide adjuncts clinicians combine with protocols.